Tarsus Pharmaceuticals (TARS) News Today $40.89 -0.06 (-0.15%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$40.88 -0.01 (-0.02%) As of 06/13/2025 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TARS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Tarsus Pharmaceuticals CCO sells $765,800 in stockJune 13 at 3:58 AM | investing.comTarsus Pharmaceuticals CCO sells $765,800 in stockJune 13 at 3:58 AM | investing.comAssenagon Asset Management S.A. Decreases Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Assenagon Asset Management S.A. decreased its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 1.9% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 1,125,305 shares of the company's stock after selling 21,507 shares during the periJune 12 at 5:58 AM | marketbeat.comE. Ohman J or Asset Management AB Boosts Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)E. Ohman J or Asset Management AB lifted its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 23.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 42,981 shares of the company's stock after buying an addJune 7, 2025 | marketbeat.comSquarepoint Ops LLC Sells 51,329 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Squarepoint Ops LLC lessened its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 89.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,004 shares of theJune 7, 2025 | marketbeat.comStocks Showing Improving Market Leadership: Tarsus Pharmaceuticals Earns 87 RS RatingJune 6, 2025 | msn.comTarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Down - Time to Sell?Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Down - What's Next?June 5, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 18.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 69,826 shareJune 5, 2025 | marketbeat.comWellington Management Group LLP Sells 8,552 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Wellington Management Group LLP trimmed its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 5.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 136,795 shares of the company's stJune 4, 2025 | marketbeat.comOppenheimer Begins Coverage on Tarsus Pharmaceuticals (NASDAQ:TARS)June 4, 2025 | americanbankingnews.comTarsus Pharmaceuticals assumed with an Outperform at OppenheimerJune 2, 2025 | msn.comTarsus Pharmaceuticals (NASDAQ:TARS) Now Covered by OppenheimerOppenheimer assumed coverage on shares of Tarsus Pharmaceuticals in a research report on Monday. They issued an "outperform" rating and a $75.00 price target on the stock.June 2, 2025 | marketbeat.comNuveen Asset Management LLC Sells 15,186 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Nuveen Asset Management LLC lessened its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 10.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 125,539 shares of the compaMay 31, 2025 | marketbeat.comQ2 Earnings Forecast for TARS Issued By HC WainwrightTarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Investment analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for Tarsus Pharmaceuticals in a note issued to investors on Tuesday, May 27th. HC Wainwright analyst M. Caufield expects that the company will poMay 30, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Purchased by Ameriprise Financial Inc.Ameriprise Financial Inc. lifted its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 21.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 47,685 shares of the company's stock aMay 30, 2025 | marketbeat.comTarsus to Participate in Upcoming Investor ConferencesMay 29, 2025 | globenewswire.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Position Lessened by Two Sigma Advisers LPTwo Sigma Advisers LP lowered its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 79.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 53,500 shares of the company's stock after selling 202,May 29, 2025 | marketbeat.comTwo Sigma Investments LP Has $5.05 Million Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Two Sigma Investments LP trimmed its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 69.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 91,171 shares of the company's stock afMay 29, 2025 | marketbeat.comTarsus Pharmaceuticals' (TARS) Buy Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and set a $72.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Tuesday.May 28, 2025 | marketbeat.comTarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)May 27, 2025 | benzinga.comTFG Asset Management GP Ltd Sells 414,117 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)TFG Asset Management GP Ltd decreased its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 67.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 200,000 shares of the compMay 27, 2025 | marketbeat.comToronto Dominion Bank Acquires New Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Toronto Dominion Bank bought a new position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 1,909,228 shares of the company's stock, valued at approximately $105,714,May 27, 2025 | marketbeat.comWoodline Partners LP Buys 37,417 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Woodline Partners LP boosted its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 52.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 108,986 shares of the company's stock after acquiring anMay 26, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Recommendation of "Buy" from BrokeragesShares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) have been assigned a consensus rating of "Buy" from the seven research firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, five have issued a buMay 25, 2025 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Cut to Hold at Wall Street ZenWall Street Zen cut Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday.May 24, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Purchased by Bank of America Corp DEBank of America Corp DE boosted its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 44.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 337,856 shares of the company's stock after buying an additionMay 23, 2025 | marketbeat.com59,204 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Purchased by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. purchased a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firmMay 22, 2025 | marketbeat.comOMERS ADMINISTRATION Corp Buys Shares of 7,400 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)OMERS ADMINISTRATION Corp bought a new position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 7,400 shares of the company's stock, valued atMay 22, 2025 | marketbeat.comTarsus Pharmaceuticals at H.C. Wainwright: Expanding Horizons with XdemvyMay 21, 2025 | investing.comMillennium Management LLC Increases Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Millennium Management LLC boosted its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 189.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 644,010 shares of the companMay 20, 2025 | marketbeat.comDeutsche Bank AG Raises Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Deutsche Bank AG raised its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 93.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 153,441 shares of the company's sMay 19, 2025 | marketbeat.comRTW Investments LP Has $179.21 Million Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)RTW Investments LP trimmed its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 5.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,236,549 shares of the compaMay 18, 2025 | marketbeat.comNumerai GP LLC Purchases Shares of 18,668 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Numerai GP LLC purchased a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 18,668 shares of the company's stock, valued at approximately $1May 17, 2025 | marketbeat.comParadigm Biocapital Advisors LP Has $140.19 Million Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Paradigm Biocapital Advisors LP lifted its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 3.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,531,896 shares of the company's stockMay 16, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Acquired by Northern Trust CorpNorthern Trust Corp increased its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 12.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 357,616 shares of the company's stocMay 16, 2025 | marketbeat.comIntegral Health Asset Management LLC Has $19.38 Million Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Integral Health Asset Management LLC reduced its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 6.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 350,000 shares of the comMay 14, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Grows Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)D. E. Shaw & Co. Inc. raised its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 100.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 365,544 shares of the company's stock after buying an additioMay 14, 2025 | marketbeat.comEnsign Peak Advisors Inc Decreases Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Ensign Peak Advisors Inc reduced its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 2.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 570,056 shares of the company's stock aftMay 13, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Schonfeld Strategic Advisors LLCSchonfeld Strategic Advisors LLC lessened its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 94.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,800 shares of the company's stMay 13, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by The Manufacturers Life Insurance CompanyThe Manufacturers Life Insurance Company lifted its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 42.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,777May 13, 2025 | marketbeat.comTarsus Pharmaceuticals: The "Get Big Fast" Approach Could Pay OffMay 12, 2025 | seekingalpha.comTudor Investment Corp ET AL Takes $769,000 Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Tudor Investment Corp ET AL acquired a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 13,880 shares of the company's stock, valuedMay 10, 2025 | marketbeat.comDimensional Fund Advisors LP Sells 62,658 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Dimensional Fund Advisors LP cut its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 15.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 341,305 shares of the company's stock after selling 62,658 shMay 10, 2025 | marketbeat.comTarsus Pharmaceuticals (TARS) to Release Quarterly Earnings on WednesdayTarsus Pharmaceuticals (NASDAQ:TARS) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 14. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-14-tarsus-pharmaceuticals-inc-stock/)May 9, 2025 | marketbeat.comCaxton Associates LP Buys New Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Caxton Associates LP purchased a new position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 16,588 shares of the company's stock, valued at approximatelMay 9, 2025 | marketbeat.comTarsus to Participate in Upcoming Investor ConferencesMay 8, 2025 | globenewswire.comCutter Capital Management LP Invests $6.23 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Cutter Capital Management LP acquired a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 112,500 shares of the company's stock, valued at approximately $6,229,0May 8, 2025 | marketbeat.comThe Goldman Sachs Group Increases Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $51.00The Goldman Sachs Group increased their target price on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a "neutral" rating in a report on Monday.May 7, 2025 | marketbeat.comVoya Investment Management LLC Purchases 18,000 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Voya Investment Management LLC boosted its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 149.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 30,033 shares of the company's stock after purchasing aMay 7, 2025 | marketbeat.comRaymond James Financial Inc. Acquires Shares of 19,999 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Raymond James Financial Inc. purchased a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 19,999 shares of the company's stock, valued at approximately $1,107,000. Raymond James FinanciaMay 7, 2025 | marketbeat.com Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Email Address TARS Media Mentions By Week TARS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TARS News Sentiment▼1.210.88▲Average Medical News Sentiment TARS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TARS Articles This Week▼46▲TARS Articles Average Week Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Elanco Animal Health News Verona Pharma News Legend Biotech News TG Therapeutics News Grifols News Lantheus News Telix Pharmaceuticals Limited American Depositary Shares News Nuvalent News Axsome Therapeutics News ADMA Biologics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TARS) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredOil Hits $74 - $100 Next?Oil Jumps 8.5% on Middle East Crisis Trump at Oil Fields Oil surged 8.5% to $74/barrel after Israel's Ir...The Oxford Club | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredAs Bitcoin supply vanishes, this Trump-aligned token could explodeBitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
